HUMAN COAGULATION FACTOR VIII, VON WILLEBRAND HUMAN COAGULATION FACTOR ( DrugBank: Human coagulation factor VIII, Factor VIII )


1 disease
IDDisease name (Link within this page)Number of trials
288Autoimmune acquired coagulation factor deficiency1

288. Autoimmune acquired coagulation factor deficiency


Clinical trials : 206 Drugs : 231 - (DrugBank : 28) / Drug target genes : 10 - Drug target pathways : 21
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-004344-28-DE
(EUCTR)
22/08/2022Clinical study to find out how well wilate works in little children with severe von Willebrand diseaseCLINICAL STUDY TO INVESTIGATE THE EFFICACY, PHARMACOKINETICS, IMMUNOGENICITY AND SAFETY OF WILATE IN SEVERE VON WILLEBRAND DISEASE PATIENTS UNDER THE AGE OF 6 YEARS Routine prophylaxis in children under the age of 6 years with severe VWD
MedDRA version: 20.0;Level: LLT;Classification code 10055168;Term: Von Willebrand's factor deficiency;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Wilate 500
Product Name: Wilate
INN or Proposed INN: Human Coagulation Factor VIII, Von Willebrand Factor
Other descriptive name: HUMAN COAGULATION FACTOR VIII, VON WILLEBRAND HUMAN COAGULATION FACTOR
Trade Name: Wilate 1000
Product Name: Wilate
INN or Proposed INN: Human Coagulation Factor VIII, Von Willebrand Factor
Other descriptive name: HUMAN COAGULATION FACTOR VIII, VON WILLEBRAND HUMAN COAGULATION FACTOR
Octapharma Pharmazeutika Produktionsges.m.b.H.NULLNAFemale: yes
Male: yes
12Phase 3Belarus;United States;Czechia;Czech Republic;Canada;Ukraine;Russian Federation;North Macedonia;Albania;Germany;Moldova, Republic of;Bosnia and Herzegovina